SMART Program for Paroxysmal Atrial Fibrillation


This is a pilot study to test the effects of the SMART-3RP (Stress Management and Resiliency Training Relaxation Response Resiliency Program) on quality of life, mental health, arrhythmia burden, and heart rate variability (HRV) in patients with paroxysmal atrial fibrillation (PAF).

Study Start Date

February, 23 2018

Estimated Completion Date

July 2020


  • Other: SMART Program

Study ID

Massachusetts General Hospital -- 2018P000015



Trial ID


Study Type


Trial Phase


Enrollment Quota



Massachusetts General Hospital

Inclusion Criteria

  • Diagnosed with documented recurrent symptomatic PAF.
  • Currently on stable medical therapy for AF and willing to continue on the same treatment regimen while participating in the study.
  • No current daily practice of yoga, meditation, guided imagery or other techniques that elicit the RR.
  • Able to provide informed consent and to understand written and spoken English.

Exclusion Criteria

  • Allergy to adhesives that prevents wearing the HRV monitor.
  • Patients unable or unwilling to participate in an intervention delivered via video conferencing.
  • End Stage renal failure or heart failure, severe unstable medical or psychiatric disease.
  • Patients deemed unable to complete protocol due to cognitive or other reasons.
  • Patients on psychoactive medications will have eligibility determined by the PI or MD co-investigator on a case-by-case basis, and will be admitted to the study if medication is deemed stable




18 Years to 90 Years

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Gillian Gadenne 617-643-6062 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.